IP Library Granted Patent US 9,475,859
Granted Patent B2
US 9,475,859 · App. 14/517,755 · Granted Oct 25, 2016

Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same

Inventors: Marianne Bruggemann (Cambridge, GB); Roland Buelow (Palo Alto, CA); Michael J. Osborn (Suffolk, GB); Biao Ma (Cambridge, GB)
Assignee: OMT, Inc.
C07K16/00A01K67/0275A01K67/0278A01K2227/105A01K2267/01C07K2317/24C07K2317/52C07K2317/56C07K2317/64C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,475,859
App. No.
14/517,755
Granted
Oct 25, 2016
Kind
B2
Abstract

The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.

Claims (17)

1. A transgenic rodent, the rodent comprising in its germline a heavy chain immunoglobulin locus comprising human unrearranged heavy chain variable region gene segments linked to DNA encoding a rodent heavy chain constant region and a rat 3′ enhancer comprising the sequence set forth as SEQ ID NO:1, wherein the heavy chain immunoglobulin locus does not comprise a human immunoglobulin constant region gene, and wherein the rodent is a mouse or a rat.

2. The rodent of claim 1 , wherein the human heavy chain variable region gene segments are contained on a DNA fragment that is larger than 170 kb.

3. The rodent of claim 1 , wherein the human heavy chain variable region gene segments are contained on a DNA fragment that is larger than 180 kb.

4. The rodent of claim 1 , wherein the human heavy chain variable region gene segments are contained on a DNA fragment that is larger than 350 kb.

5. The rodent of claim 1 , wherein the human unrearranged heavy chain variable region gene segments are capable of rearranging to form a functional heavy chain variable region gene.

6. The rodent of claim 5 , wherein following rearrangement the rodent expresses a functional antigen-binding molecule encoded by the human gene segments.

7. The rodent of claim 1 , wherein the rodent produces an antibody that comprises a human variable region and a rodent constant region.

8. The rodent of claim 1 , wherein the rodent is a rat.

9. The rodent of claim 1 , wherein the rodent heavy chain constant region is a rodent Fc region.

10. A method of producing an antibody having a human variable region and a rodent constant region comprising exposing a transgenic rodent to an antigen, the rodent comprising in its germline a heavy chain immunoglobulin locus comprising human unrearranged heavy chain variable region gene segments linked to DNA encoding a rodent heavy chain constant region and a rat 3′ enhancer comprising the sequence set forth as SEQ ID NO:1, wherein the heavy chain immunoglobulin locus does not comprise a human immunoglobulin constant region gene, wherein the exposure to the antigen is such that the transgenic rodent produces an antibody to the antigen, the antibody having a human heavy chain variable region and a rodent heavy chain constant region, and wherein the rodent is a mouse or a rat.

11. The method of claim 10 , wherein the human heavy chain variable region gene segments are contained on a DNA fragment that is larger than 170 kb.

12. The method of claim 10 , wherein the human heavy chain variable region gene segments are contained on a DNA fragment that is larger than 180 kb.

13. The method of claim 10 , wherein the human heavy chain variable region gene segments are contained on a DNA fragment that is larger than 350 kb.

14. The method of claim 10 , wherein the rodent is a rat.

15. The method of claim 10 , wherein the rodent heavy chain constant region is a rodent Fc region.

16. The method of claim 10 , further comprising the step of making a hybridoma from the transgenic rodent, the hybridoma comprising DNA encoding the antibody.

17. The method of claim 16 , wherein the hybridoma is made from the spleen of the transgenic rodent.

Assignments (4)
CHANGE OF NAME Recorded Nov 16, 2022
From: OMNIAB, INC.
To: OMNIAB OPERATIONS, INC.
Reel/Frame 061954/0411 →
CHANGE OF NAME Recorded Mar 17, 2022
From: OPEN MONOCLONAL TECHNOLOGY, INC.
To: OMNIAB, INC.
Reel/Frame 059435/0119 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 036200 FRAME 0024. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 18, 2016
From: BRUGGEMANN, MARIANNE; BUELOW, ROLAND; OSBORN, MICHAEL J.; MA, BIAO
To: OPEN MONOCLONAL TECHNOLOGY, INC.
Reel/Frame 040648/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2015
From: BRUGGEMANN, MARIANNE; BUELOW, ROLAND; OSBORN, MICHAEL J.; MA, BIAO
To: OMT, INC.
Reel/Frame 036200/0024 →
Continuity (3)
Continuation PCTUS2013075157 · Dec 13, 2013
Provisional Application 61737371 · Dec 14, 2012
Related Publication 20150113668A1 · Apr 23, 2015